What it treats (GSM)
Genitourinary syndrome of menopause (GSM), formerly called atrophic vaginitis, is the cluster of symptoms caused by declining estrogen at the vulvovaginal and urethral tissues:
- Vaginal dryness, itching, burning
- Painful intercourse (dyspareunia)
- Urinary urgency, frequency
- Recurrent UTIs (atrophic tissue is more susceptible)
- Stress incontinence
- Mild pelvic organ prolapse symptoms
- Reduced libido (partly mechanical)
GSM affects 50-70% of postmenopausal women and is progressive without treatment.
How it works locally
Vaginal tissue is rich in estrogen receptors. Local estradiol restores tissue thickness, elasticity, vascular tone, and the normal acidic pH of the vaginal microbiome, which protects against UTIs. The effect is anatomical reversal of atrophy, not just symptom masking.
Negligible systemic absorption
Properly dosed local vaginal estrogen produces serum estradiol levels essentially identical to baseline postmenopausal levels. Systemic exposure is on the order of 1/100th of typical systemic HRT. This is why the safety profile is dramatically different from systemic HRT, many of the systemic concerns simply don't apply.
Breast cancer survivors
Current oncology guidance, including from ASCO and the Endocrine Society, supports local vaginal estrogen for many breast cancer survivors with severe GSM symptoms, particularly after non-hormonal options have failed. The decision is shared with oncology, but it's no longer the absolute contraindication it was once treated as.
Available forms
| Form | Use |
|---|---|
| Estradiol cream | Applied intravaginally and to vulva; flexible dosing |
| Estradiol vaginal tablet (Vagifem, Yuvafem) | Inserted twice weekly after loading; clean and dose-controlled |
| Estradiol ring (Estring) | Replaced every 90 days; once-and-done convenience |
| DHEA insert (Intrarosa) | Converts to local estrogen; alternative for some patients |
| Compounded vaginal cream | Customized dosing through 503A pharmacies |
Typical dosing
- Cream: 0.5-1 g intravaginally + small amount to vulva, 2-3x weekly after initial 2-week daily loading
- Tablet: one tablet daily for 2 weeks, then twice weekly
- Ring: insert and replace every 90 days
What to expect
- Week 1-2: tissue starts rehydrating; some symptom relief
- Week 4-8: significant improvement in dryness, dyspareunia, urinary symptoms
- Month 3+: full effect; UTI frequency drops dramatically
- Lifelong use is appropriate, symptoms return if discontinued
The clinical pearl: Vaginal estrogen is one of the highest benefit-to-risk interventions in women's medicine. Its underuse is a public health problem driven mostly by women not knowing it exists.
Bottom line
Local vaginal estrogen is a safe, effective, often-overlooked treatment for genitourinary symptoms of menopause. The systemic exposure is minimal; the local benefit is dramatic. Suitable for most postmenopausal women including many who can't use systemic HRT. Talk to a clinician, most women suffering with these symptoms are unaware of how easily and safely they can be resolved.